# OnCo record basal-cell-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/basal-cell-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "basal-cell-carcinoma" ;
  schema:name "Basal cell carcinoma"@en ;
  schema:alternateName "BCC"@en, "Basal Cell Carcinoma of the Skin"@en ;
  schema:description "Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."@en ;
  schema:url <https://onco.cc/cancers/basal-cell-carcinoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Basal-cell_carcinoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q809758> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1416>, <https://doi.org/10.1056/NEJMoa1113713>, <https://www.cancer.gov/types/skin/patient/skin-treatment-pdq> ;
  onco:tag "gap-fill", "skin" ;
  onco:related <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/merkel-cell-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/technologies/dermoscopy-ai/>, <https://onco.cc/technologies/black-salve-escharotics/> ;
  onco:targets <https://onco.cc/targets/smoothened/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/sonidegib/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/imiquimod/>, <https://onco.cc/drugs/aminolevulinic-acid/>, <https://onco.cc/drugs/nicotinamide/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/sanofi/>, <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/philogen-s-p-a/> ;
  onco:pathways <https://onco.cc/pathways/basal-cell-carcinoma-signalling/> ;
  onco:terms <https://onco.cc/terms/irae/> ;
  onco:trials <https://onco.cc/trials/nct06050122/> ;
  onco:pipeline <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/vismodegib/> ;
  onco:standardOfCare <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/sonidegib/>, <https://onco.cc/drugs/cemiplimab/> .